Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ARQT

Arcutis Biotherapeutics Inc

May 07 • 11:09AM ET

22.40

-1.77 -7.32 %

Healthcare • Biotechnology • USA • Mid • NASD

Today, 3:08 AMArcutis posts Q1 2026 non-GAAP EPS -$0.09 on revenue $105.4M, misses EPS but beats revenue estimates, maintains 2026 guidance and highlights infant AD expansion

Peers: BMRN ANAB RCUS BCRX TVRD CNTA DERM VERU SLNO KZIA

| Held by: XBI VTI IWM VXF IWO IBB VTWO SCHA VHT FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.14	Insider Own	11.84%	Shs Outstand	123.33M	Perf Week	-3.53%
Market Cap	2.80B	Forward P/E	20.53	EPS next Y	1.09	Insider Trans	-2.94%	Shs Float	110.27M	Perf Month	-8.98%
Enterprise Value	2.69B	PEG	-	EPS next Q	0.05	Inst Own	96.13%	Short Float	15.04%	Perf Quarter	-14.08%
Income	-16.14M	P/S	7.45	EPS this Y	269.23%	Inst Trans	4.19%	Short Ratio	13.19	Perf Half Y	-6.71%
Sales	376.07M	P/B	14.58	EPS next Y	396.02%	ROA	-4.13%	Short Interest	16.58M	Perf YTD	-22.87%
Book/sh	1.54	P/C	12.66	EPS next 5Y	-	ROE	-9.30%	52W High	31.77 -29.49%	Perf Year	63.50%
Cash/sh	1.77	P/FCF	-	EPS past 3/5Y	71.80% 49.34%	ROIC	-5.33%	52W Low	12.42 80.35%	Perf 3Y	53.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	367.27% -	Gross Margin	90.24%	Volatility	4.02% 4.00%	Perf 5Y	-34.37%
Dividend TTM	-	EV/Sales	7.17	EPS Y/Y TTM	88.80%	Oper. Margin	-3.25%	ATR (14)	1.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.99	Sales Y/Y TTM	91.34%	Profit Margin	-4.29%	RSI (14)	42.36	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.17	EPS Q/Q	248.38%	SMA20	-5.40%	Beta	1.58	Target Price	34.62
Payout	-	Debt/Eq	0.60	Sales Q/Q	81.48%	SMA50	-5.13%	Rel Volume	3.41	Prev Close	24.17
Employees	354	LT Debt/Eq	0.60	Earnings	May 06 AMC	SMA200	-2.68%	Avg Volume	1.26M	Price	22.40
IPO	Jan 31, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-39.97% 1.66%	Trades		Volume	1,248,920	Change	-7.32%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Initiated	Goldman	Neutral	$18
Dec-30-24	Initiated	H.C. Wainwright	Buy	$19
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

May-06-26 04:00PM	Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -7.32%
Apr-27-26 08:00AM	Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months (GlobeNewswire)
Apr-22-26 08:00AM	Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines (GlobeNewswire)
Apr-15-26 04:00PM	Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 (GlobeNewswire)
Mar-31-26 04:00PM	Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +10.45%
11:00AM	Loading…
Mar-28-26 11:00AM	Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-26-26 05:20PM	Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating (Investor's Business Daily) -5.18%
Mar-18-26 08:00AM	Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-10-26 09:00AM	Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology (GlobeNewswire)
Mar-06-26 10:20AM	Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating (Insider Monkey)
Mar-05-26 09:00AM	Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth (GlobeNewswire)
Mar-04-26 08:09AM	Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen (MarketBeat)
Mar-03-26 08:00AM	Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis (GlobeNewswire)
Feb-27-26 04:00PM	Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference (GlobeNewswire) -5.60% -8.19%
Feb-26-26 08:30AM	Arcutis Biotherapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) +5.78%
12:04AM	Loading…
12:04AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-25-26 07:25PM	Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
06:32PM	Arcutis Biotherapeutics Q4 Earnings Call Highlights (MarketBeat)
04:00PM	Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 09:15AM	Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments (GlobeNewswire)
07:22AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-19-26 10:00AM	Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-18-26 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-11-26 06:02PM	Arcutis Biotherapeutics Touts ZORYVE Expansion, New Indications and 2026 Cash-Flow Breakeven Goal (MarketBeat)
Feb-10-26 08:32AM	Implied Volatility Surging for Arcutis Biotherapeutics Stock Options (Zacks)
Feb-05-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 08:00AM	Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis (GlobeNewswire)
Jan-27-26 08:16AM	Arcutis Biotherapeutics announces termination of promotion agreement with Kowa (TipRanks)
Jan-26-26 08:00AM	Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa (GlobeNewswire)
04:00PM	Loading…
Jan-22-26 04:00PM	Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference (GlobeNewswire)
Jan-21-26 08:00AM	Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions (GlobeNewswire)
Jan-13-26 04:21AM	Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength? (Zacks)
Jan-12-26 08:00AM	Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones (GlobeNewswire) -5.10%
Dec-19-25 09:40AM	Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? (Zacks)
Dec-18-25 03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-14-25 09:35AM	This Biotech Stock Could Cure Your Portfolio's Pain (Motley Fool)
Dec-10-25 12:00PM	What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? (Zacks)
Dec-08-25 04:00PM	Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri (GlobeNewswire)
10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks)
10:30AM	Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status (Zacks)
Dec-05-25 10:37AM	ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study (Zacks)
10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks)
Dec-04-25 09:47AM	Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know (Zacks)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
10:01AM	AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension (Zacks)
09:40AM	Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
10:12AM	Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock? (Zacks)
10:09AM	JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis (Zacks)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
Nov-28-25 09:33AM	Netflix target cut, Five Below target raised: Wall Street's top analyst calls (The Fly)
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 03:47AM	Why Shares in Arcutis Biotherapeutics Surged Again This Week (Motley Fool) +7.90%
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
09:49AM	MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC (Zacks)
09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? (Zacks)
Nov-19-25 10:06AM	VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects (Zacks)
Nov-18-25 11:42AM	VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know (Zacks)
10:33AM	Alector Stock Plummets 63% in a Month: Here's What You Need to Know (Zacks)
Nov-17-25 09:41AM	Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year? (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average (Zacks)
08:00AM	FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 (GlobeNewswire)
Nov-15-25 08:00AM	CrowdStrike Leads Five Stocks To Watch Near Buy Points (Investor's Business Daily)
Nov-14-25 07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +9.36%
Nov-13-25 09:08AM	Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint (Zacks)
08:00AM	Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis (GlobeNewswire)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
Nov-07-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:27AM	Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised (Zacks)
11:22AM	ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down (Zacks)
10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
11:18AM	TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up (Zacks)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
10:01AM	Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down (Zacks)
09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade (Zacks)
Nov-04-25 10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
08:00AM	Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology (GlobeNewswire)
Oct-31-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-30-25 12:00PM	What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock (Zacks)
09:40AM	Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments (GlobeNewswire)
08:00AM	Arcutis Launches ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
Oct-29-25 09:08AM	Arcutis (ARQT) Soars to Record High on Swing to Profitability, 'More-Than-Double' Revenues (Insider Monkey)
Oct-28-25 12:00PM	Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today (Motley Fool) +27.04%
11:37AM	Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. (Investor's Business Daily)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates (Zacks)
08:30AM	Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-27-25 04:00PM	Arcutis to Present at Upcoming Investor Conferences (GlobeNewswire)
09:30AM	What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q3 2025 Earnings (GuruFocus.com)
Oct-24-25 08:00AM	Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-21-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-06-25 08:00AM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
06:41AM	Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Oct-03-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.26%
Oct-01-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-29-25 04:00PM	Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 (GlobeNewswire) +5.98%

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Matsuda Masaru	See Remarks	May 04 '26	Sale	23.31	8,256	192,415	126,689	May 06 07:40 PM
Burnett Patrick	See Remarks	May 04 '26	Sale	23.61	684	16,150	120,466	May 06 06:15 PM
Vairavan Latha	SVP Chief Financial Officer	May 04 '26	Sale	23.61	1,341	31,662	86,413	May 06 06:13 PM
Watanabe Todd	See Remarks	May 04 '26	Sale	23.61	3,172	74,893	720,755	May 06 06:06 PM
Welgus Howard G.	Director	May 01 '26	Sale	22.99	7,144	164,220	32,600	May 05 08:21 PM
Patrick Burnett	Officer	May 04 '26	Proposed Sale	23.61	684	16,150		May 04 05:19 PM
Latha Vairavan	Officer	May 04 '26	Proposed Sale	23.61	1,341	31,662		May 04 05:18 PM
Todd Watanabe	Officer	May 04 '26	Proposed Sale	23.61	3,172	74,893		May 04 05:18 PM
Masaru Matsuda	officer	May 04 '26	Proposed Sale	23.31	8,256	192,416		May 04 05:05 PM
Howard Welgus	Director	May 01 '26	Proposed Sale	22.99	7,144	164,220		May 01 04:04 PM
Welgus Howard G.	Director	Apr 01 '26	Sale	23.88	10,000	238,801	39,744	Apr 03 05:46 PM
Howard Welgus	Director	Apr 01 '26	Proposed Sale	23.88	10,000	238,801		Apr 01 04:02 PM
Leonard Keith R	Director	Mar 02 '26	Option Exercise	8.28	39,272	325,231	61,395	Mar 04 04:17 PM
Leonard Keith R	Director	Mar 02 '26	Sale	25.39	39,272	997,195	22,123	Mar 04 04:17 PM
Welgus Howard G.	Director	Mar 02 '26	Sale	25.65	10,000	256,518	49,744	Mar 04 04:16 PM
Edwards Larry Todd	See Remarks	Mar 02 '26	Sale	25.18	3,687	92,846	175,178	Mar 03 08:43 PM
Watanabe Todd	See Remarks	Mar 02 '26	Sale	25.18	37,349	940,528	785,957	Mar 03 08:42 PM
Matsuda Masaru	See Remarks	Mar 02 '26	Sale	25.30	8,733	220,943	136,932	Mar 03 08:42 PM
Matsuda Masaru	See Remarks	Feb 27 '26	Sale	27.95	3,325	92,934	143,678	Mar 03 08:42 PM
Vairavan Latha	SVP Chief Financial Officer	Mar 02 '26	Sale	25.18	2,853	71,844	87,754	Mar 03 08:42 PM
Burnett Patrick	See Remarks	Mar 02 '26	Sale	25.18	6,287	158,320	121,150	Mar 03 08:41 PM
Masaru Matsuda	officer	Mar 02 '26	Proposed Sale	26.03	12,058	313,878		Mar 02 06:48 PM
Larry Todd Edwards	Officer	Mar 02 '26	Proposed Sale	25.18	3,687	92,846		Mar 02 06:22 PM
Todd Watanabe	Officer	Mar 02 '26	Proposed Sale	25.18	37,349	940,526		Mar 02 06:22 PM
Latha Vairavan	officer	Mar 02 '26	Proposed Sale	25.18	2,853	71,845		Mar 02 06:22 PM
Patrick Burnett	Officer	Mar 02 '26	Proposed Sale	25.18	6,287	158,320		Mar 02 06:21 PM
Keith Leonard	Board of Director	Mar 02 '26	Proposed Sale	25.39	39,272	997,195		Mar 02 05:59 PM
Howard Welgus	Director	Mar 02 '26	Proposed Sale	25.65	10,000	256,518		Mar 02 05:25 PM
Matsuda Masaru	See Remarks	Feb 02 '26	Sale	25.28	40,638	1,027,293	110,003	Feb 04 08:35 PM
Burnett Patrick	See Remarks	Feb 04 '26	Sale	25.81	9,794	252,748	80,651	Feb 04 07:30 PM
Burnett Patrick	See Remarks	Feb 02 '26	Sale	25.50	3,675	93,707	90,445	Feb 04 07:30 PM
Watanabe Todd	See Remarks	Feb 02 '26	Sale	25.50	19,833	505,710	721,306	Feb 04 07:25 PM
Vairavan Latha	SVP Chief Financial Officer	Feb 02 '26	Sale	25.50	1,320	33,658	63,607	Feb 04 07:24 PM
Welgus Howard G.	Director	Feb 02 '26	Sale	25.05	10,000	250,483	59,744	Feb 04 07:23 PM
Edwards Larry Todd	See Remarks	Feb 02 '26	Sale	25.50	2,052	52,323	148,865	Feb 04 07:21 PM
Patrick Burnett	Officer	Feb 04 '26	Proposed Sale	25.81	9,794	252,748		Feb 04 04:52 PM
Masaru Matsuda	officer	Feb 02 '26	Proposed Sale	25.28	40,638	1,027,275		Feb 02 06:19 PM
Todd Edwards	Officer	Feb 02 '26	Proposed Sale	25.50	2,052	52,323		Feb 02 06:17 PM
Latha Vairavan	Officer	Feb 02 '26	Proposed Sale	25.50	1,320	33,658		Feb 02 06:15 PM
Patrick Burnett	Officer	Feb 02 '26	Proposed Sale	25.50	3,675	93,707		Feb 02 05:48 PM
Todd Frank Watanabe	officer	Feb 02 '26	Proposed Sale	25.50	19,833	505,710		Feb 02 05:41 PM
Howard Welgus	Director	Feb 02 '26	Proposed Sale	25.05	10,000	250,483		Feb 02 05:04 PM
Burnett Patrick	See Remarks	Jan 05 '26	Sale	28.98	2,490	72,166	94,120	Jan 07 05:46 PM
Welgus Howard G.	Director	Jan 02 '26	Sale	28.96	10,000	289,606	69,744	Jan 06 05:31 PM
Patrick Burnett	Officer	Jan 05 '26	Proposed Sale	28.98	2,490	72,166		Jan 05 04:01 PM
Burnett Patrick	See Remarks	Dec 31 '25	Sale	29.20	1,697	49,560	96,610	Jan 02 06:12 PM
Howard Welgus	Director	Jan 02 '26	Proposed Sale	28.96	10,000	289,606		Jan 02 04:00 PM
Patrick Burnett	Officer	Dec 31 '25	Proposed Sale	29.21	1,697	49,561		Dec 31 04:01 PM
Burnett Patrick	See Remarks	Dec 15 '25	Option Exercise	3.64	11,500	41,860	109,807	Dec 17 05:53 PM
Burnett Patrick	See Remarks	Dec 15 '25	Sale	28.94	11,500	332,851	98,307	Dec 17 05:53 PM
Patrick Burnett	Officer	Dec 15 '25	Proposed Sale	28.94	11,500	332,851		Dec 15 04:07 PM
Matsuda Masaru	See Remarks	Dec 01 '25	Sale	30.23	1,657	50,091	150,641	Dec 03 05:24 PM
Welgus Howard G.	Director	Dec 01 '25	Sale	30.21	10,000	302,133	79,744	Dec 03 05:23 PM
Howard Welgus	Director	Dec 01 '25	Proposed Sale	30.21	10,000	302,133		Dec 01 04:07 PM
Masaru Matsuda	Officer	Dec 01 '25	Proposed Sale	30.23	1,657	50,091		Dec 01 04:06 PM
LIN SUE-JEAN	Director	Nov 24 '25	Option Exercise	8.31	25,272	210,011	52,007	Nov 25 06:27 PM
LIN SUE-JEAN	Director	Nov 24 '25	Sale	30.78	25,272	777,956	26,735	Nov 25 06:27 PM
Watanabe Todd	See Remarks	Nov 24 '25	Sale	30.36	48,945	1,485,755	740,537	Nov 24 06:45 PM
Watanabe Todd	See Remarks	Nov 21 '25	Sale	30.00	1,055	31,650	793,838	Nov 24 06:45 PM
Sue-Jean Lin	Director	Nov 24 '25	Proposed Sale	30.78	25,272	777,956		Nov 24 04:01 PM
Todd Franklin Watanabe	Officer	Nov 24 '25	Proposed Sale	30.36	48,945	1,485,755		Nov 24 03:55 PM
Matsuda Masaru	See Remarks	Nov 19 '25	Sale	28.29	2,550	72,135	151,476	Nov 21 06:34 PM
Gilbert Halley E	Director	Nov 20 '25	Option Exercise	7.51	12,220	91,772	38,655	Nov 21 06:21 PM
Gilbert Halley E	Director	Nov 20 '25	Sale	27.55	16,532	455,442	22,123	Nov 21 06:21 PM
Todd Franklin Watanabe	Officer	Nov 21 '25	Proposed Sale	30.00	1,055	31,650		Nov 21 04:49 PM
Halley Gilbert	Director	Nov 20 '25	Proposed Sale	27.55	16,532	455,442		Nov 20 04:24 PM
Masaru Matsuda	Officer	Nov 19 '25	Proposed Sale	28.29	2,550	72,133		Nov 19 04:20 PM
Krishnamohan Neha	Director	Nov 13 '25	Option Exercise	8.28	39,272	325,231	62,627	Nov 17 07:56 PM
Krishnamohan Neha	Director	Nov 13 '25	Sale	23.20	40,504	939,494	22,123	Nov 17 07:56 PM
Neha Krishnamohan	Director	Nov 13 '25	Proposed Sale	23.19	40,504	939,273		Nov 13 04:05 PM
Edwards Larry Todd	See Remarks	Nov 06 '25	Sale	25.16	29,131	732,927	150,193	Nov 10 05:42 PM
Burnett Patrick	See Remarks	Nov 06 '25	Option Exercise	3.64	17,250	62,790	115,575	Nov 10 05:41 PM
Burnett Patrick	See Remarks	Nov 06 '25	Sale	24.18	17,250	417,145	98,325	Nov 10 05:41 PM
Patrick Burnett	Officer	Nov 06 '25	Proposed Sale	24.18	17,250	417,145		Nov 06 05:49 PM
Burnett Patrick	See Remarks	Nov 05 '25	Sale	23.72	3,864	91,643	98,325	Nov 05 06:57 PM
Burnett Patrick	See Remarks	Nov 03 '25	Sale	24.72	2,622	64,806	102,189	Nov 05 06:57 PM
Welgus Howard G.	Director	Nov 03 '25	Sale	25.27	10,000	252,669	89,744	Nov 05 06:24 PM
Vairavan Latha	SVP Chief Financial Officer	Nov 03 '25	Sale	24.72	88	2,175	64,927	Nov 05 06:24 PM
Watanabe Todd	See Remarks	Nov 03 '25	Sale	24.72	11,547	285,399	794,893	Nov 05 06:23 PM
Matsuda Masaru	See Remarks	Nov 03 '25	Sale	24.72	7,208	178,156	154,026	Nov 05 06:23 PM
Patrick Burnett	Officer	Nov 05 '25	Proposed Sale	23.72	3,846	91,216		Nov 05 05:29 PM
Masaru Matsuda	Officer	Nov 03 '25	Proposed Sale	24.72	7,208	178,155		Nov 03 05:49 PM
Latha Vairavan	Officer	Nov 03 '25	Proposed Sale	24.72	88	2,175		Nov 03 05:48 PM
Todd Franklin Watanabe	Officer	Nov 03 '25	Proposed Sale	24.72	11,547	285,399		Nov 03 05:47 PM
Patrick Burnett	Officer	Nov 03 '25	Proposed Sale	24.72	2,622	64,806		Nov 03 05:47 PM
Howard Welgus	Director	Nov 03 '25	Proposed Sale	25.27	10,000	252,669		Nov 03 04:52 PM
Watanabe Todd	See Remarks	Oct 28 '25	Sale	25.03	40,000	1,001,032	806,440	Oct 30 07:02 PM
Todd F watanabe	officer	Oct 28 '25	Proposed Sale	25.03	40,000	1,001,033		Oct 28 04:06 PM
Edwards Larry Todd	See Remarks	Oct 02 '25	Sale	20.04	4,504	90,263	178,897	Oct 06 03:15 PM
Watanabe Todd	See Remarks	Oct 01 '25	Sale	19.33	24,261	469,074	867,179	Oct 03 05:02 PM
Watanabe Todd	See Remarks	Oct 02 '25	Sale	20.04	20,739	415,574	846,440	Oct 03 05:02 PM
Welgus Howard G.	Director	Oct 01 '25	Option Exercise	1.68	9,538	16,030	109,744	Oct 03 05:01 PM
Welgus Howard G.	Director	Oct 01 '25	Sale	18.92	10,000	189,227	99,744	Oct 03 05:01 PM
Todd Franklin Watanabe	Officer	Oct 02 '25	Proposed Sale	20.04	20,739	415,574		Oct 02 04:43 PM
Larry Todd Edwards	officer	Oct 02 '25	Proposed Sale	20.04	4,504	90,263		Oct 02 04:41 PM
Todd Franklin Watanabe	Officer	Oct 01 '25	Proposed Sale	19.33	24,261	469,074		Oct 01 05:35 PM
Howard Welgus	Director	Oct 01 '25	Proposed Sale	18.92	10,000	189,227		Oct 01 03:16 PM
Watanabe Todd	See Remarks	Sep 08 '25	Sale	17.54	9,625	168,799	891,944	Sep 10 06:21 PM
Watanabe Todd	See Remarks	Sep 09 '25	Sale	17.52	504	8,829	891,440	Sep 10 06:21 PM
Watanabe Todd	Officer	Sep 09 '25	Proposed Sale	17.52	504	8,829		Sep 09 03:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARQT

Arcutis Biotherapeutics Inc

Upgrade your Finviz experience